

Image S1. Examples of clinical decision support alerts for patients with *CYP2C19* rapid metabolizer status. The top example is the alert that activates for an adult patient, while the bottom example is the alert that activates for a pediatric patient.

BestPractice advisory

SANFORD imagenetics Voriconazole is not recommended due to risk of therapeutic failure.

Consider alternative agent.
Reference: Moriyama, et al. Guidelines for CYP2C19 and voriconazole therapy. July 2017.

Remove the following orders? Voriconazole (VFEND) 200 mg tablet
Take 1 tablet (200 mg) by mouth, R-0.

© 2019 Epic Systems Corporation. Used with permission.

BestPractice advisory

SANFORD imagenetics Patient is at risk of therapeutic failure with voriconazole use.

Probability of attaining therapeutic drug concentrations is variable. Initiate therapy with standard dosing but consider therapeutic drug monitoring. Consider alternative medication if possible.
Reference: Moriyama, et al. Guidelines for CYP2C19 and voriconazole therapy. July 2017.

Remove the following orders? Voriconazole (VFEND) in dextrose 5% 250 ml
Administer intravenously, R-0

© 2019 Epic Systems Corporation. Used with permission.